Filana Therapeutics, Inc.
FLNA Nasdaq
SEC CIK 1069530
Follow Filana Therapeutics
Weekly email: filings, results
Net income
−$10.7M
+0.7% vs same quarter last year
EPS, diluted
−$0.22
+0% vs same quarter last year
Operating cash flow
−$6.1M
+2% vs same quarter last year
Operating income
−$11.3M
+4.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$91M |
| FY24 | - | −$24.3M |
| FY23 | - | −$97.2M |
| FY22 | - | −$76.2M |
| FY21 | - | −$32.4M |
| FY20 | - | −$6.3M |
| FY19 | - | −$4.6M |
| FY18 | - | −$6.6M |
| FY17 | - | −$11.9M |
| FY16 | - | −$14.9M |
| FY15 | - | −$14.1M |
| FY14 | - | −$12.4M |
| FY13 | $41.1M | $31.5M |
| FY12 | $10.9M | −$3.4M |
| FY11 | $11.5M | −$2.6M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | 76.3% | 76.7% |
| FY12 | −35.8% | −31.6% |
| FY11 | −30.6% | −22.8% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$32.8M |
| FY24 | −$117M |
| FY23 | −$82.4M |
| FY22 | −$80.2M |
| FY21 | −$52.4M |
| FY20 | - |
| FY19 | −$2.5M |
| FY18 | - |
| FY17 | - |
| FY16 | −$12.3M |
| FY15 | −$9.2M |
| FY14 | −$9.6M |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Filana Therapeutics
- Healthcare median
Show the numbers
| Year | Filana Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | 76.7% | −37.1% |
| FY12 | −31.6% | −29.1% |
| FY11 | −22.8% | −27.9% |